lapatinib has been researched along with diphenhydramine in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (diphenhydramine) | Trials (diphenhydramine) | Recent Studies (post-2010) (diphenhydramine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 4,146 | 415 | 542 |
| Protein | Taxonomy | lapatinib (IC50) | diphenhydramine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.98 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.542 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 1.05 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.372 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.162 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.346 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.647 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.542 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.295 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.98 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.171 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.118 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.8852 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
1 review(s) available for lapatinib and diphenhydramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for lapatinib and diphenhydramine
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |